Disease Modifying Anti-rheumatic Drugs,DMARDs Mycophenolate Pharmacology Physiotherapy

Mycophenolate and PML

In this article we will discuss Mycophenolate and PML

In this article, we will discuss Mycophenolate and PML. So, let’s get started.

Mycophenolate and Progressive Multifocal Leukoencephalopathy (PML)

Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with CellCept. Hemiparesis, apathy, confusion, cognitive deficiencies and ataxia were the most frequent clinical features observed. The reported cases generally had risk factors for PML, including treatment with immunosuppressant therapies and impairment of immune function. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms and consultation with a neurologist should be considered as clinically indicated. Consideration should be given to reducing the amount of immunosuppression in patients who develop PML. In transplant patients, physicians should also consider the risk that reduced immunosuppression represents to the graft.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.